MV 1

MV1 is an antagonist of IAP. When combined with HaloTag ligand, MV1 causes protein knockdown of HaloTag-fused proteins.

MV-1-NH-Me, an MV-1-derived IAP ligand, connects to an ABL inhibitor through a linker, resulting in the formation of SNIPER[1].

Compound 12k (THP-1/MV-4-11 against-1) is a 5-substituted thiazolyl urea anticancer agent with significant inhibitory efficacy against THP-1/MV-4-11 cancer cells, demonstrating IC50 values of 29 nM and 98 nM, respectively.

Jmv 167 is an antagonist of the Cholecystokinin receptor.

Jmv 170 is the C-terminal heptapeptide of cholecystokinin. It has partial agonist CCK activity on pancreatic amylase release.

Jmv 179 is an antagonist of the cholecystokinin receptor.

Jmv 176 is a CCK agonist when first given and becomes a cholecystokinin antagonist after 3-4 hours.

Jmv 180, a CCK analog, can distinguish high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.

Poly(acrylic acid) (Mv 100000) is a reagent used in biochemical reactions.

MV151 is a cell-permeable, fluorescent, broad-spectrum proteasome inhibitor that specifically targets all active subunits of the proteasome and immunoproteasome in living cells and can be used to label the proteasome in vitro and in vivo.

RG7713 (RO 5028442) has been used in trials studying Autistic Disorder.

Balovaptan (RG7314) is a highly potent and selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors. It is used for the research of autism.

MMV1088447 is a novel inhibitor of parasite growth. This compound shares characteristics with cells treated with nuclear hormone receptor (NHR) agonists/antagonists. By reducing host lipid metabolism, MMV1088447 significantly impedes the growth of parasites.

MMV1578877 is an inhibitor of Mycobacterium ulcerans with an IC50 of 0.37 μM. It is applicable in research related to Buruli ulcer (BU).

JMV-1645 is an effective and selective B(1) bradykinin receptor antagonist.

JMV-1609 is a bioactive chemical.

Macimorelin Acetate (EP-1572), an orally active growth hormone (GH) secretagogue and a ghrelin receptor (GHSR) agonist, stimulates GH release. It is utilized in research focusing on adult growth hormone deficiency (AGHD) and Cancer Anorexia-Cachexia Syndrome (CACS).

MMV1557817 is an orally active compound that is effective against malaria. The compound exhibits good selective inhibition of aminopeptidases M1 and M17 of Plasmodium falciparum and Plasmodium vivax, and can effectively block the digestion of hemoglobin by asexual malarial parasites at the end of their life cycle.

MMV1634566 is an effective antimalarial agent that can inhibit Plasmodium falciparum and exhibits cytotoxicity.

Prexasertib (LY2606368) is a selective checkpoint kinase 1 (CHK1) inhibitor (Ki 0.9 nM, IC50<1 nM). Prexasertib causes double-stranded DNA breaks and replication mutations, leading to apoptosis. Prexasertib has antitumor activity.

GNE-207 is a selective and orally bioavailable inhibitor of the bromodomain of CBP (IC50: 1 nM). It has a selective index of >2500-fold against BRD4 (1). GNE-207 displays excellent CBP potency (EC50: 18 nM for MYC expression in MV-4-11 cells).

SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5 μM [1].

SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a DC50 of 0.3 μM[1].

SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels, achieving a DC50 value of 2 μM[1].